User profiles for "author:Xavier Montalban"
Xavier MontalbanVerified email at cem-cat.org Cited by 93029 |
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
AJ Thompson, BL Banwell, F Barkhof… - The Lancet …, 2018 - thelancet.com
The 2010 McDonald criteria for the diagnosis of multiple sclerosis are widely used in
research and clinical practice. Scientific advances in the past 7 years suggest that they might …
research and clinical practice. Scientific advances in the past 7 years suggest that they might …
Defining the clinical course of multiple sclerosis: the 2013 revisions
Accurate clinical course descriptions (phenotypes) of multiple sclerosis (MS) are important
for communication, prognostication, design and recruitment of clinical trials, and treatment …
for communication, prognostication, design and recruitment of clinical trials, and treatment …
MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines
In patients presenting with a clinically isolated syndrome, MRI can support and substitute
clinical information in the diagnosis of multiple sclerosis by showing disease dissemination …
clinical information in the diagnosis of multiple sclerosis by showing disease dissemination …
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria
CH Polman, SC Reingold, B Banwell… - Annals of …, 2011 - Wiley Online Library
New evidence and consensus has led to further revision of the McDonald Criteria for
diagnosis of multiple sclerosis. The use of imaging for demonstration of dissemination of …
diagnosis of multiple sclerosis. The use of imaging for demonstration of dissemination of …
[HTML][HTML] Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis
Background Fingolimod (FTY720), a sphingosine-1-phosphate–receptor modulator that
prevents lymphocyte egress from lymph nodes, showed clinical efficacy and improvement …
prevents lymphocyte egress from lymph nodes, showed clinical efficacy and improvement …
[HTML][HTML] Ocrelizumab versus placebo in primary progressive multiple sclerosis
Background An evolving understanding of the immunopathogenesis of multiple sclerosis
suggests that depleting B cells could be useful for treatment. We studied ocrelizumab, a …
suggests that depleting B cells could be useful for treatment. We studied ocrelizumab, a …
[HTML][HTML] Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis
Background B cells influence the pathogenesis of multiple sclerosis. Ocrelizumab is a
humanized monoclonal antibody that selectively depletes CD20+ B cells. Methods In two …
humanized monoclonal antibody that selectively depletes CD20+ B cells. Methods In two …
[HTML][HTML] Oral fingolimod (FTY720) for relapsing multiple sclerosis
Background Fingolimod (FTY720) is a new oral immunomodulating agent under evaluation
for the treatment of relapsing multiple sclerosis. Methods We randomly assigned 281 …
for the treatment of relapsing multiple sclerosis. Methods We randomly assigned 281 …
2021 MAGNIMS–CMSC–NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis
MP Wattjes, O Ciccarelli, DS Reich, B Banwell… - The Lancet …, 2021 - thelancet.com
Summary The 2015 Magnetic Resonance Imaging in Multiple Sclerosis and 2016
Consortium of Multiple Sclerosis Centres guidelines on the use of MRI in diagnosis and …
Consortium of Multiple Sclerosis Centres guidelines on the use of MRI in diagnosis and …
Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis
In 85% of young adults with multiple sclerosis (MS), onset is a subacute clinically isolated
syndrome (CIS) of the optic nerves, brainstem, or spinal cord. Methods of assessing the …
syndrome (CIS) of the optic nerves, brainstem, or spinal cord. Methods of assessing the …